1	Measles incidence in South Africa: a six-year review, 2015 - 2020
2	Short title: Measles in South Africa
3	
4	Mukhlid Yousif <sup>1,2*</sup> , Heather Hong <sup>1</sup> , Susan Malfeld <sup>1</sup> , Sheilagh Smit <sup>1</sup> , Lillian Makhathini <sup>1</sup> , Tshepo Motsamai <sup>1</sup> ,
5	Dipolelo Tselana <sup>1</sup> , Morubula Manamela <sup>1</sup> , Mercy Kamupira <sup>3,4</sup> , Elizabeth Maseti <sup>5</sup> , Kennedy Otwombe <sup>6,7</sup> ,
6	Kerrigan McCarthy <sup>1,7</sup> , Melinda Suchard <sup>1,8</sup>
7	<sup>1</sup> Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health
8	Laboratory Service, Johannesburg, South Africa.
9	<sup>2</sup> Department of Virology, School of Pathology, Faculty of Health Sciences, University of the
10	Witwatersrand, Johannesburg, South Africa.
11	<sup>3</sup> World Health Organization, Pretoria, South Africa.
12	<sup>4</sup> UNICEF, Pretoria, South Africa
13	<sup>5</sup> Child, Youth and School Health, National Department of Health, Pretoria, South Africa.
14	<sup>6</sup> Perinatal HIV Research Unit, Chris Hani Baragwanath Academic Hospital, University of the
15	Witwatersrand, Johannesburg, South Africa
16	<sup>7</sup> School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
17	South Africa
18	<sup>8</sup> Department of Chemical Pathology, School of Pathology, University of the Witwatersrand,
19	Johannesburg, South Africa.
20	* Corresponding author
21	Dr Mukhlid Yousif
22	Centre for Vaccines and Immunology
23	National Institute for Communicable Diseases

24 Researcher, Virology department

- 25 Faculty of Health Sciences
- 26 University of the Witwatersrand
- 27 Tel: +27 11 386 6461
- 28 Email: <u>mukhlidy@nicd.ac.za</u>

29

30 **Keywords**: vaccination, incidence rate, rash, vaccine, elimination, febrile

31

#### 33 Abstract

In 2012 the World Health Organization (WHO) aimed to eliminate measles in five regions by 2020. This
 retrospective descriptive study reviewed measles surveillance data in South Africa for the period 2015 2020 to document the epidemiology of measles and the progress made towards meeting the 2020
 measles elimination goal.

38 A total of 22,578 specimens were tested over the period 2015 - 2020 yielding 401 (1.8%) confirmed 39 measles cases, 321 (1.4%) compatible and 21,856 (96.8%) discarded cases. The most affected age group 40 was 0-4 year olds. At the provincial level, South Africa achieved adequate surveillance, defined as more than two cases of febrile rash notified annually per 100 000 popoulation, except for KwaZulu-Natal and 41 42 Limpopo in 2020, probably due to COVID-19 lockdown restrictions. Of confirmed cases, only 26% were 43 vaccinated, 3% were too young to receive vaccines, 5% were not vaccinated, and 65% had vaccination 44 status unknown. Measles vaccine effectiveness amongst 1-4 year olds was 80%. Using the standard case 45 definition, South Africa achieved the measles elimination target of less than one case per one million 46 nationally in years 2015, 2016 and 2020. The years 2017 to 2019 had incidence rates exceeded one per 47 million nationally. Using a narrow case definition, that excluded positive rubella cases, improved the indicators with only the year 2017 having an incidence rate of more than one per million. 48

South Africa displays intermittent measles outbreaks approximately six-yearly interspersed by interepidemic periods in which the country meets measles elimination targets. Intense effort is needed to increase the vaccine coverage to avoid periodic outbreaks. Enhanced molecular testing of each case will be required as measles incidence declines regionally.

53

#### 55 Introduction

Measles is a highly contagious airborne disease that affects the upper respiratory tract. Measles is caused by the rubeola virus, a member of the *Morbillivirus* genus, *Paramyxoviridae* family (1). Transmission occurs through direct contact with infectious droplets or by airborne spread when an infected person breathes, coughs, or sneezes. After exposure, the first sign of measles is usually a high fever, followed by runny nose, cough and rash (2). In young children less than five years , around 30% of measles infections can lead to complications such as diarrhoea, otitis media, pneumonia, encephalitis, seizures and death (3).

Before the development of a measles vaccine in the 1960s, measles was a leading cause of morbidity and 63 64 mortality (4). Measles was responsible for more than two million deaths annually (5). Despite the 65 availability of the vaccine, measles remains a leading cause of death in children under five years of age 66 (6). Measles outbreaks still occur in countries where vaccination coverage is low (7). According to the 67 WHO, in 2018, more than 140,000 people died due to measles, of which at least one third were in Africa 68 (7). In 2012, the WHO updated the measles elimination initiative aiming to eliminate measles by 2020 in 69 at least five of six global regions (8). The WHO defined the elimination of measles as the absence of 70 indigenous measles cases in a certain geographic region for up to 12 months in the presence of a high-71 quality surveillance system (ref?). The WHO also requires national measles vaccination coverage of 95% 72 in all districts with two doses of measles vaccine per child. At least 80% of districts should investigate one 73 or more suspected cases within a year and should report a non-measles rash illness rate of at least two 74 cases per 100, 000 nationally (9).

In South Africa, the measles vaccine is available in single antigen formulation in the public sector or in combination format with mumps and rubella antigens (MMR) in private sector. In 1975, the measles vaccine was first administered as one dose at nine months of age. In 1995, when the immunization

programme was expanded, a second dose was added at 18 months. In 2016, the schedule changed to 78 79 earlier administration at 6 and 12 months of age (10). Post the introduction of the expanded programme 80 of immunization, several measles outbreaks have occurred. Between 2003 and 2005, an outbreak 81 occurred with 1,676 cases reported (11). In 2009-2010, a large outbreak occurred with 18,431 82 documented cases (12). In 2017, a small outbreak occurred with measles cases detected in Western Cape, 83 Gauteng and Kwazulu-Natal provinces, with a total number of 186 infected (10). In 2019, a cluster of 84 measles infection in four siblings who travelled to Georgia was detected in Cape Town (13). 85 Correspondingly, between 2012 and 2017 the measles 1<sup>st</sup> dose measles vaccination coverage in South Africa averaged 71.7%, while measles 2<sup>nd</sup> dose vaccination averaged 68.8% (14). Since then, measles 2<sup>nd</sup> 86 87 dose coverage increased to 76.4% in 2018 but remains below the 95% coverage level required for 88 elimination, thus sporadic cases still occur.

As part of febrile rash surveillance, any suspected case of measles seen by a clinician should be notified within 24 hours and a blood specimen should be collected and sent to the National Institute for Communicable Diseases (NICD) for testing. Febrile rash cases thus comprise multiple aetiologies, the common of which in the South African setting is rubella. In this manuscript we review the febrile surveillance data for the period 2015 to 2020, to document the epidemiology of measles in South Africa, and the progress made towards national measles elimination. Rubella incidence has been previously reported (Hong et al, submitted)

#### 96 Methods

#### 97 <u>Study design</u>

A retrospective descriptive study was conducted to review measles surveillance data in South Africa for
 the period 2015- 2020 to document the epidemiology of measles and the progress made towards
 meeting the 2020 measles elimination goal. Ethical approval was obtained from the Human Research

101	Ethics committee of the Unversity of the Witwatersrand, under: : "essential communicable disease
102	surveillance and outbreak investigation activities of the National Institute for Communicable Disease of
103	(NICD) of South Africa".

#### 104 <u>Case-based Surveillance</u>

For all suspected measles cases meeting the case definition of febrile rash with at least one of the symptoms; cough, coryza or conjunctivitis, or in any patient in whom a clinician suspected measles, a case investigation form (CIF) was required to be filled and sent to the NICD along with a serum sample. Throat swab and/ or urine samples were not routinely collected during this period.

#### 109 Specimen testing

110 All serum samples were tested for measles immunoglobulin M (IgM) and rubella IgM using a commercial 111 Enzyme-Linked Immunosorbent Assay (ELISA) according to manufacturer instructions. For the period 2015 112 to 2017, sera were tested using Enzygnost<sup>®</sup> kits (Siemens AG, Erlangen, Germany). For the period 2018 to 113 2020, sera were tested using Euroimmun<sup>®</sup> kits (Euroimmun AG, Luebeck, Germany). A second specimen 114 was requested following any equivocal results for measles IgM. From the period 2017 to 2020, all sera 115 that tested positive or equivocal for measles IgM were also tested for the presence of measles virus 116 genome by RT-PCR. Ideally, the specimens of choice for measles RT-PCR are throat swabs and urine 117 specimens, however, sera occasionally yield positive results. Measles genotyping to differentiate wild 118 from vaccine strains was conducted for any RT-PCR positive samples (RT-PCR cycle threshold (CT) value 119 <35). Genotyping was performed by amplifying 450 nucleotides of the nucleocapsid region followed by 120 sequencing and phylogenetic analysis (15).

#### 121 <u>Case Classification</u>

Based on the laboratory and epidemiological investigations, suspected measles cases were classified as follows: (i) discarded, when the case did not meet the clinical or laboratory definition (measles IgM

negative, vaccine-associated [within five weeks of measles vaccine, or had vaccine strain present]) (ii) compatible, when the case met the clinical case definition, was not epidemiologically linked, but no blood specimen was received, or blood specimen was equivocal (iii) confirmed, when the case was laboratory-confirmed (measles IgM positive and/or PCR positive). In this study we only report on the laboratory-confirmed cases and do not further discuss the compatible cases, due to the heterogeneous nature of febrile rash aetiology in years with no large measles outbreaks.

130 In South Africa rubella rubella virus is endemic and rubella vaccination is not part of the expanded 131 programme of immunization. The most common cause of febrile morbilliform rash in our setting is 132 therefore rubella. Cross-reactive measles serology is well described, where measles IgM may be falsely 133 elevated during intercurrent infection with rubella (16). Due to overlapping clinical symptoms, such cases are usually classified as both "confirmed measles" and "confirmed rubella" cases due to the difficulty of 134 135 excluding a measles diagnosis and the need to err on the side of caution regarding early measles outbreak 136 response. We have therefore reported our laboratory confirmed measles cases using two definitions – 137 firstly all laboratory-confirmed measles cases (standard definition as per WHO guidelines), secondly after 138 exclusion of cases that were dual positive for rubella IgM (narrow definition).

#### 139 Data analysis

Data were captured and analyzed in Microsoft Excel 2016. A descriptive analysis was performed.
Categorical data were reported as frequencies or percentages, while continuous data were reported as
median and interquartile range (IQR).

#### 143 Vaccine effectiveness

Vaccine effectiveness was determined using the narrow case definition to exclude confounding by rubella
 cases. Vaccine effectiveness was calculated among 1-4 year olds, only due to predominantly missing

vaccine information in older age groups. Vaccine efficacy (VE) was estimated using the formula VE=((ARU-ARV)/ARU) \* 100 where ARU was the measles attack rate in the unvaccinated population and ARV was
the measles attack rate in the vaccinated population. Factors associated with measles infection were
determined by univariate and multivariate logistic regression. Analysis was conducted for cases occurring
up to 2016 and after 2016, due to the vaccine schedule change that occurred in 2016. Statistical analysis
was conducted using SAS Enterprise Guide 7.15 (SAS Institute, Cary, NC, USA) assuming a 0.05 level of
significance.

#### 153 Results

Of the 22,578 patients tested over the period 2015 - 2020, 11,179 (49.5%) were males, 10,782 (47.8%) were females and 617 (2.7%) had unknown sex. The median age was 5.0 (IQR 3.0-8.0) years. Measles IgM tested positive in 465 (2.1%) samples, equivocal in 433 (1.9%) and negative for 21,386 (94.7%) samples. Over the period between 2017 to 2020, 454 real-time PCR tests were performed, of which 143 (31.5%) were positive. Among the PCR positive cases, 40 specimens were subjected to a genotyping assay, of which 39 were determined as genotype D8 and one specimen was genotype B3, which was an imported case from Saudi Arabia (10).

Of the total of 899 cases that tested positive or equivocal for measles IgM and/or positive for measles PCR, 401 (44.6%) were classified as laboratory-confirmed measles cases, 321 (35.7%) were compatible, and 166 (18.5%) were discarded. Of the confirmed cases 28.9% (116/401) also tested positive for rubella IgM.

Figure 1 shows the trend of confirmed measles cases over the six years (2015 - 2020). Measles cases ranged from 0 to 14 per month, with exception of 2017, in which confirmed cases ranged from 3 to 28 per month, corresponding with an outbreak (Figure 1A). After excluding rubella positive cases, measles cases ranged from 0 to 7 per month except in 2017 (Figure 1B). Measles cases occurred mostly in the age group

- 169 of 0-4 years (n=148, 37.0%), and 20-44 years (n=105, 26.2%) (Figure 2). The age-standardized incidence
- 170 rates showed that the group 0-4 years had the highest incidence rates (**Table 1**). The sex distribution
- among the age groups did not show any significant pattern.
- 172 Figure 1 caption: Monthly incidence of measles infection in South Africa during 2015-2020. Figure 1A
- 173 shows confirmed measles cases including rubella positive cases. **Figure 1B** shows confirmed measles cases
- 174 excluding rubella cases. Figure 2 captions: Age and sex distribution among measles cases identified during
- 175 2015-2020. Figure 2A includes cases dual positive for rubella IgM. Figure 2B shows cases excluding rubella
- 176 IgM positive cases.

#### 177 Table 1: Age-specific incidence rates of laboratory-confirmed measles in South Africa, 2015-

			Rate per million population				
Age group	Measles cases	Population	Standard case definition (Including dual positive for rubella	Narrow case definition (Excluding positive rubella			
			2015				
0_4	14	5,936,350	2.4	2.2			
5_9	1	5,537,225	0.2	0.0			
10_14	1	5,138,468	0.2	0.2			
15_19	0	5,124,373	0	0.0			
20_44	3	21,822,066	0.1	0.1			
>45	2	11,398,439	0.2	0.2			
Total	21	54,956,921	0.4	0.3			
			2016				
0_4	5	5,862,896	0.9	0.9			
5_9	3	5,761,111	0.5	0.3			
10_14	0	5,183,234	0	0.0			
15_19	1	4,873,874	0.2	0.2			
20_44	8	22,659,494	0.4	0.3			
>45	1	11,568,256	0.1	0.1			
Total	18	55,908,865	0.3	0.3			
			2017				
0_4	51	5,866,573	8.7	7.8			
5_9	31	5,76,4576	5.4	3.5			
10_14	18	5,093,681	3.5	3.3			

15_19	22	4,592,001	4.8	4.4
20_44	73	23,439,277	3.1	3.1
>45	8	11,765,840	0.7	0.7
Total	203	5,652,1948	3.6	3.2
		· · ·	2018	
0_4	41	5,928,951	6.9	3.0
5_9	14	5,862,081	2.4	0.3
10_14	0	5,252,485	0	0.0
15_19	0	4,733,790	0	0.0
20_44	9	23,681,676	0.4	0.3
>45	1	12,266,622	0.1	0.1
Total	65	57,725,605	1.1	0.5

			Rate per million population			
Age group	Measles cases	Population	Standard case definition	Narrow case definition		
			(Including dual positive for rubella	(Excluding positive rubella)		
			2019			
0_4	31	5,733,946	5.4	1.9		
5_9	12	5,737,439	2.1	0.0		
10_14	5	5,427,902	0.9	0.4		
15_19	4	4,660,002	0.9	0.9		
20_44	12	24,137,303	0.5	0.2		
>45	3	13,078,429	0.2	0.2		
Total	67	5,877,5021	1.1	0.4		
			2020			
0_4	6	5,743,450	1.0	0.7		
5_9	13	5,715,952	2.3	0.5		
10_14	2	5,591,553	0.4	0.4		
15_19	1	4,774,579	0.2	0.2		
20_44	0	24,418,106	0.0	0.0		
>45	0	13,378,710	0.0	0.0		
Total	22	59,622,350	0.4	0.2		

180 Blocks shaded in grey show incidence rates that exceeded one case per million population. Population

figures as per mid-year population estimates 2020 (statistics South Africa, 2020). Measles cases shown

in column two were all laboratory-confirmed.

183 Gauteng province had the highest number of confirmed measles cases (n=141, 35.2%) followed by

184 KwaZulu-Natal (n=95, 23.7%), Western Cape (n=67, 16.7%), Eastern Cape (n=28, 7.0%), North West (n=26,

185 6.5%), Free State (n=13, 3.2%), Mpumalanga (n=11, 2.7%), while Northern Cape, and Limpopo had the

186 least number of cases (n=10, 2.1%). To understand the provincial incidence rates we calculated the

number of cases per million population by using the population midyear estimates (17) (**Table 2**).

Year	201	15	201	L6	201	L7	201	18	201	19	20	20
Cases	Standard	Narrow										
Eastern Cape	0.4	0.4	0.0	0.0	0.9	0.8	0.6	0.2	1.3	0.0	0.9	0.3
Free State	0.4	0.4	0.0	0.0	0.3	0.3	1.7	1.0	1.4	0.3	0.7	0.0
Gauteng	0.5	0.5	0.7	0.7	6.3	6.1	0.9	0.6	0.9	0.5	0.6	0.4
KwaZulu-Natal	0.2	0.1	0.3	0.3	4.8	4.1	1.9	0.7	1.1	0.3	0.3	0.2
Limpopo	0.2	0.0	0.0	0.0	0.5	0.5	0.5	0.5	0.5	0.3	0.0	0.0
Mpumalanga	0.0	0.0	0.2	0.2	0.7	0.2	1.1	0.7	0.2	0.2	0.2	0.0
North West	0.3	0.3	0.3	0.3	3.1	2.6	0.8	0.3	7.1	1.6	0.0	0.0
Northern Cape	2.5	2.5	0.0	0.0	0.0	0.0	2.4	0.0	0.5	0.0	1.5	0.8
Western Cape	0.8	0.8	0.6	0.3	5.4	5.5	1.2	0.3	2.0	1.3	0.1	0.0
South Africa	0.4	0.4	0.3	0.3	3.6	3.2	1.1	0.5	1.2	0.4	0.4	0.2

### 189 Table 2: Provincial incidence rates of laboratory-confirmed measles during 2015-2020

190 Incidence rate per one million population in each province using wide and narrow case definition. The standard definition for measles infection

included measles IgM or RT-PCR positive cases with dual positive IgM serology for rubella, while the narrow definition excluded cases with

192 positive rubella IgM serology. Blocks shaded in grey indicate rates of more than one, which are higher than the WHO pre-elimination target.

193

194

196 The WHO elimination goal of less than one measles case per one million population was achieved in each

- 197 province in 2015, 2016 and 2020, except in Northern Cape in 2015. However, in the years 2017, 2018 and
- 198 2019 many provinces had more than one case per million (Table 2). Repeating the same analysis excluding
- 199 cases in which rubella IgM was dual positive yielded incidence rates above one per million in 2017 in most
- 200 provinces, and in Free State in 2018, North West and Western Cape in 2019 (Table 2).
- 201 According to the WHO, surveillance adequacy should be measured by the number of non-measles febrile
- rash illness cases reported per 100,000 population. More than two cases per 100,000 population is
- 203 required for adequate surveillance. Using this indicator, South Africa achieved adequate surveillance
- indicator target throughout 2015 2020, except in KwaZulu-Natal and Limpopo in 2020, corresponding
- to the lockdown imposed due to the COVID-19 restrictions (**Table 3**).

Province	2015	2016	2017	2018	2019	2020
Eastern Cape	8.49	4.26	4.72	8.31	7.73	2.0
Free State	5.07	2.34	5.27	3.22	6.82	2.3
Gauteng	7.81	7.85	11.77	5.25	6.08	2.0
KwaZulu-Natal	3.78	2.36	12.15	8.85	4.79	1.4
Limpopo	3.68	4.60	6.61	2.54	2.54	1.0
Mpumalanga	8.12	5.94	14.09	6.76	7.21	3.4
North West	8.34	4.77	9.60	4.75	85.53	2.8
Northern Cape	26.06	11.50	27.76	13.14	2.83	3.9
Western Cape	7.94	3.72	13.21	7.31	10.07	2.9
South Africa	7	4.9	10.7	6.4	7.7	2.1

Table 3: Surveillance adequacy per province during 2015-2020

207 Non-measles febrile rash surveillance per 100,000 population in each province. Blocks shaded in grey
 208 indicate rates less than two, which are lower than the WHO recommended minimum febrile rash case

209 target.

210

Additional indicators showed only 105 (26%) of laboratory-confirmed cases were measles vaccinated, 22

(5%) were not measles vaccinated, 14 (3%) were too young (< 6 months) for measles vaccination, and

213 measles vaccination status of 260 (65%) were unknown. Among the group in which measles vaccination

was reported, 25 (24%) received only one dose, 53 (50%) had two or more doses, and 28 (27%) had an
unknown number of doses. Repeating this analysis after exclusion of cases who were dual positive for
rubella IgM, only 45 (16%) were vaccinated, of which 17 (41%) had two doses. Among measles negative
samples, measles vaccination status was unknown in 13887 (63%) of cases. CIFs were submitted with
specimens in 192 (48%) cases, unique EPID numbers were submitted in 204 (51%) cases, and only 141
(35%) cases had both CIF and unique EPID number (Table 4).

### Table 4: Surveillance indicators for laboratory-confirmed measles and non-measles cases

Status		Confirmed measles cases (standard definition) (n=401)	%	Confirmed measles cases (narrow case definition) (n=285)	%	non-measles (22,177)	%
	Тоо						
	young <6						
Measles vaccination	m	14	3	7	2	713	3
	Unknown	260	65	219	77	13,887	63
	Yes	105	26	45	16	7,327	33
	No	22	5	14	5	250	1
	1	25	24	19	42	726	10
Measles vaccine doses	2 or						
weasies vaccine doses	more	53	50	17	38	4,628	63
	Unknown	28	27	5	11	1,972	27
Case investigation form		192	48	118	41	10,853	49
Epidemiological number		204	51	124	44	11,343	51
Case investigation form							
and epidemiological							
number		141	35	84	29	7,444	34

222 Standard case definition included all laboratory-confirmed (IgM positive or PCR positive) measles cases, including those dual positive for rubella

223 IgM. Narrow case definition included all laboratory-confirmed (IgM positive or PCR positive) measles cases, excluding those dual positive for

rubella IgM. Non-measles cases are febrile rash cases that tested negative for measles.

225

- 227 Over the period of 2015 2020, South Africa failed to meet the WHO recommendation for immunization
- 228 coverage target of children under one-year-old. South Africa had less than 95% coverage in all provinces
- over the period 2015-2019 except Gauteng in 2015. Vaccination coverage was below 90% in three districts
- in South Africa between November 2020 and January 2021 (19). Of note, vaccination coverage was the
- lowest in 2017, corresponding with the 2017 measles outbreak (18).
- Of the 22,587 febrile rash cases, there were 8,127 (36.0%) aged 1-4 years old with the majority being
- females (Table 5).

## 235Table 5: Factors associated with measles diagnosis among children 1-4 years old

			Univariate		Multivariate	
	Overall	Measles cases	OR (95% CI)	p-value	OR (95% CI)	p-value
Gender, n (%)						
Male	4411 (54.28)	24/4079 (0.59)	Ref		Ref	
Female	3716 (45.72)	35/3393 (1.03)	1.76 (1.05-2.97)	0.0334	2.06 (1.20-3.55)	0.0090
Vaccinated, n (%)						
Yes	3575 (98.08)	20/3321 (0.60)	Ref		-	
No	70 (1.92)	2/68 (2.94)	5.00 (1.15-21.84)	0.0323	-	
Number of measles vaccines, n (%)						
1 dose	329 (12.35)	4/303 (1.32)	2.60 (0.822-8.207)	0.1041	-	
2 doses	2334 (87.65)	11/2146 (0.51)	Ref		-	
Vaccination year, n (%)						
< 2016	1814 (50.74)	6/1774 (0.34)	Ref		-	
≥ 2016	1761 (49.26)	14/1547 (0.90)	2.323 (1.299-4.152)	0.0045	-	
Age years median (IQR) (n)	3 (2-4) (n=7904)	2 (1-3) (n=56)	0.671 (0.529-0.852)	0.0010	0.668 (0.526-0.847)	0.0009

238 Overall, the median (IQR) age of febrile rash cases was 3 (2-4) years whereas that of those with measles 239 was 2 (1-3) years. Multivariate logistic regression showed that compared to males, females had a higher 240 odds of measles infection (OR: 2.06, 95% CI: 1.20-3.55, p=0.009) whereas each year of age reduced the 241 odds of infection (OR: 0.67, 95% CI: 0.53-0.85, p=0.0009). The measles vaccine effectiveness among 1-4 242 year olds was 80%. On univariate analysis, the odds of measles cases being unvaccinated compared with 243 vaccinated was 5.00 (95%CI: 1.15-21.84, p=0.0323) although measles vaccination status was no longer a 244 significant predictor of measles infection on multivariate analysis. Using univariate analysis, the 245 probability of infection with measles after vaccination was higher after 2016 compared to the previous 246 programme before 2016 (p=0.0045), although the vaccination year was no longer significant on 247 multivariate analysis.

#### 248 Discussion

In this review, we aimed to evaluate the level of South Africa's readiness to eliminate measles. We reviewed six years' retrospective data from the national surveillance programme for febrile rash illness. Between the years 2015 to 2020, a total of 285 confirmed measles cases (excluding rubella infections) were detected in South Africa, with the highest incidence rate of 6.1 cases per million detected in 2017 in Gauteng province, while the lowest incidence rate of infection was zero detected in many provinces in multiple years (**Table 2**).

Younger children aged from 0-4 years were the most affected age group. Stratified by population figures, the highest incidence rate was in the age group of 0-4 years at 7.8 per million in 2017, 3.0 per million in 2018, and 1.9 per million in 2019, however in 2017 all age groups had had high incidence rates, with many adult cases, due to the outbreak that affected the country (**Table 1**). In 2017, one death was reported (ref?) but outcome data for most cases was not available.

In the past six years, South Africa had a good surveillance system in place, evidenced by the adequate non-measles rash surveillance rate of more than 2.0 per 100,000 population in all provinces from 2015 to 2020, except in 2020 in KwaZulu-Natal and Limpopo, which had a rate of 1.4 and 1.0 per 100,000 respectively. This reduction of the rate of non-measles rash surveillance was probably due to the lockdown from March to August imposed because of the COVID-19 pandemic, resulting in reduced healthseeking behavior but also lowering the transmission of respiratory-borne viruses. The non-measles rash surveillance in South Africa in 2020 was 2.1 per 100,000, still above the recommended threshold.

267 On the other hand, certain indicators were poorly performed such as the completion of CIF, assignment 268 of unique EPID number, and completion of vaccination information of confirmed and discarded measles 269 cases. In addition, the national immunization coverage of vaccination in all provinces did not reach 95% 270 coverage (18). Imperfect vaccine coverage explains the circulation of measles cases.

271 Interestingly, choice of the measles case definition plays an important role in evaluating the status of 272 South Africa's measles elimination goals. Using the standard case definition, South Africa only achieved 273 the elimination target of an incidence rate of less than one case per one million nationally in the years 274 2015, 2016 and 2020. The years 2017 to 2019 had incidence rates greater than one per million nationally. 275 Conversely, using a narrow case definition that excluded positive rubella cases from the analysis improved 276 the indicators. Only the year 2017 had an incidence rate of more than one per million. In years 2018 and 277 2019 South Africa kept the incidence rate below one, which means the country is approaching achieving 278 the measles elimination goals. In the year 2020, all provinces had had a rate below one per million 279 populations, which could be explained by COVID-19 restrictions and interruption of the spread of 280 respiratory illnesses generally due to social distancing, increased hygiene measures and lockdowns, or by 281 hesitation in seeking medical services during lockdown periods.

282 While we cannot definitively conclude that all dual positive measles and rubella samples were due to 283 rubella rather than measles, rubella is more common in the South African setting, and therefore the 284 positive predictive value of a positive rubella IgM result is higher than the positive predictive value of a 285 positive measles IgM result. With relatively few measles cases diagnosed, additional confirmatory tests 286 are required to confirm measles positive results, thus our results excluding the dual positive cases is likely 287 the more accurate estimate.

288 Conducting measles and rubella serology on all samples is a strength of our study and allowed us to 289 differentiate between samples positive only for measles and those positive for both measles and rubella. 290 Cross-reactive serology occurs reasonably uncommonly using the ELISA methodology, however, the 291 influence of false-positive serology can form a large proportion of cases when overall measles numbers 292 are low and rubella numbers high. Of note, cross-reactive measles and rubella serology has been reported 293 with most commercial assays (16) (20)(21) and likely represents biological increases in polyclonal antibody 294 titres in patients in vivo, rather than in vitro flaws of the diagnostic kits. Such challenges indicate the need 295 for improved molecular diagnostics for routine measles surveillance in South Africa, necessitating future 296 collection of throat swabs, urine samples or other suitable samples for confirmatory measles molecular 297 testing. Rubella vaccine introduction to South Africa is likely within the next few years and may alleviate 298 testing ambiguities.

Using the narrow case definition, which excluded the rubella positive cases, measles vaccine effectiveness in South Africa was determined as 80% among children aged between 1-4 years old. This is low compared to other studies that reported vaccine effectiveness of 95%, using large datasets (22) (23). Our results also showed that the odds of being vaccinated and having measles was hifher prior to 2016, when children received vaccine at 9 months and 18 months, compared to post 2016 when children receive the vaccine at 6 months and 12 months. Early vaccination might blunt the immune response to subsequent measles vaccine doses (24). Ongoing evaluation of vaccine effectiveness with the new schedule is warranted. A

306 confounder of these results may be that the measles cases in our dataset occurred mostly during the 2017 307 outbreaks, resulting in most measles cases in our dataset occurring after 2017. Our work is also limited by 308 missing information in our programmatic data, particularly the number of respondents with available 309 information on measles vaccination status and of doses. Nevertheless, our program data provides a good 310 reflection of the impact of the vaccine program in a routine setting. 311 In conclusion, the results of this study suggested that more effort is needed to increase the vaccine 312 coverage in the country as well as the completion of indicators including clinical investigation form, unique 313 EPID number and information on vaccination status in febrile rash cases. Improvements in laboratory 314 confirmatory measles diagnostic assays will also be required to meet the goals for measles elimination. 315 Moreover, catch-up vaccinations will be needed to fill the gaps particularly following the COVID-19

316 pandemic in which many children missed their routine immunizations.

317 Funding

318 There was no specific research funding for this study.

319

#### 320 Authors contributions

321 MY: performed data curation, performed analysis, wrote manuscript, edit and reviewed manuscript. HH:

322 co-conceplized study, performed data curation, reviewed manuscript. SM: performed data curation,

323 reviewed manuscript . SS: performed data curation, reviewed manuscript. LM: performed data curation,

324 review manuscripted. TM: performed data curation, reviewed manuscript. DT: performed data curation,

- 325 reviewed manuscript. MM: performed data curation, reviewed manuscript. MK: performed data
- 326 curation, reviewed manuscript. EM: performed data curation, reviewed manuscript. KO: performed
- 327 analysis, reviewed manuscript. KM: performed analysis, reviewed manuscript. MS: co-conceplized study,

328 performed analysis, reviewed manuscript.

### 330 Acknowledgements

- 331 We acknowledge the support and contribution by the provincial expanded programme on Immunisation
- 332 coordinators, and the provincial communicable disease control teams, notifiable medical conditions
- teams. We also thank the staff of Center for Vaccines and Immunology at the NICD.

334		References
335	1.	Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol A J Pathol Soc Gt Britain Irel.
336		2006;208(2):199–214.
337	2.	Battegay R, Itin C, Itin P. Dermatological Signs and Symptoms of Measles: A Prospective Case
338		Series and Comparison with the Literature. Dermatology [Internet]. 2012;224(1):1–4. Available
339		from: https://www.karger.com/DOI/10.1159/000335091
340	3.	CDC. Measles [Internet]. 2020. Available from:
341		https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html#measles
342	4.	Moss WJ. Measles. Lancet [Internet]. 2017;390(10111):2490–502. Available from:
343		http://www.sciencedirect.com/science/article/pii/S0140673617314630
344	5.	WHO. Measles and Rubella Global Strategic Plan 2012-2020 Midterm Review [Internet]. 2015.
345		Available from:
346		https://www.who.int/immunization/sage/meetings/2016/october/1_MTR_Report_Final_Color_S
347		ept_20_v2.pdf
348	6.	WHO. Measles, fact sheet [Internet]. 2019. Available from: https://www.who.int/news-
349		room/fact-sheets/detail/measles
350	7.	WHO. Joint News Release:More than 140,000 die from measles as cases surge worldwide
351		[Internet]. 2019. Available from: https://www.who.int/news/item/05-12-2019-more-than-140-
352		000-die-from-measles-as-cases-surge-worldwide
353	8.	WHO. Global measles and rubella strategic plan: 2012. 2012;
354	9.	Masresha B, Luce R, Shibeshi M, Katsande R, Fall A, Okeibunor J, et al. Status of measles
355		elimination in eleven countries with high routine immunisation coverage in the WHO African
356		region. J Immunol Sci. 2018;140.
357	10.	Hong H, Makhathini L, Mashele M, Malfeld S, Motsamai T, Sikhosana L, et al. Annual measles and

- 358 rubella surveillance review, South Africa, 2017. Natl Inst Commun Dis Public Heal Surveill Bull.
- 359 2017;16(2):64–77.
- 11. McMorrow ML, Gebremedhin G, Van den Heever J, Kezaala R, Harris BN, Nandy R. Measles

361 outbreak in South Africa, 2003-2005. South African Med J. 2009;99(5).

- 12. Ntshoe GM, McAnerney JM, Archer BN, Smit SB, Harris BN, Tempia S, et al. Measles outbreak in
- 363 South Africa: epidemiology of laboratory-confirmed measles cases and assessment of
- 364 intervention, 2009-2011. PLoS One [Internet]. 2013/02/20. 2013;8(2):e55682–e55682. Available
- 365 from: https://pubmed.ncbi.nlm.nih.gov/23437059
- 13. Hong HA E. Annual measles, rubella and congenital rubella survellance review, South Africa,
- 367 2019. 2020; Available from: https://www.nicd.ac.za/wp-content/uploads/2020/06/ANNUAL-
- 368 MEASLES-RUBELLA-AND-CONGENITAL-RUBELLA-SURVEILLANCE-REVIEW-SOUTH-AFRICA-
- 369 2019.pdf 18(1).

370 14. WHO. Experts caution against stagnation of immunization coverage in Africa [Internet]. 2019.


- 371 Available from: https://www.afro.who.int/news/experts-caution-against-stagnation-
- 372 immunization-coverage-africa
- 15. del Mar Mosquera M, Echevarría JE, Puente S, Lahulla F, de Ory F. Use of whole blood dried on
- filter paper for detection and genotyping of measles virus. J Virol Methods. 2004;117(1):97–9.
- 16. Hübschen JM, Bork SM, Brown KE, Mankertz A, Santibanez S, Mamou M Ben, et al. Challenges of
- 376 measles and rubella laboratory diagnostic in the era of elimination. Clin Microbiol Infect.
- 377 2017;23(8):511–5.
- statistics south africa. Mid-Year Population Estimates 2020 [Internet]. Pretoria; 2020. Available
   from: http://www.statssa.gov.za/?p=13453
- 18. Massyn N, Day C, Ndlovu N, Padayachee T. District Health Barometer 2019/20. 2020; Available
- 381 from: https://www.hst.org.za/publications/District Health Barometers/DHB 2019-20 Complete

382 Book.pdf

- 383 19. UNICEF. Uneven routine immunization coverage threatens the health of South Africa's youngest
- 384 children [Internet]. 2021. Available from: https://www.unicef.org/southafrica/press-
- 385 releases/uneven-routine-immunization-coverage-threatens-health-south-africas-youngest
- 386 20. Hiebert J, Zubach V, Charlton CL, Fenton J, Tipples GA, Fonseca K, et al. Evaluation of Diagnostic
- 387 Accuracy of Eight Commercial Assays for the Detection of Measles Virus-Specific IgM Antibodies.
- 388 J Clin Microbiol. 2021;59(6):e03161-20.
- 389 21. Thomas HIJ, Barrett E, Hesketh LM, Wynne A, Morgan-Capner P. Simultaneous IgM reactivity by
- 390 EIA against more than one virus in measles, parvovirus B19 and rubella infection. J Clin Virol.
- 391 1999;14(2):107–18.
- 392 22. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in
   393 children. Evidence-Based Child Heal A Cochrane Rev J. 2013;8(6):2076–238.
- 23. Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps,


rubella, and varicella in children. Cochrane Database Syst Rev. 2020;(4).

- 396 24. Lochlainn LMN, de Gier B, van der Maas N, van Binnendijk R, Strebel PM, Goodman T, et al. Effect
- 397 of measles vaccination in infants younger than 9 months on the immune response to subsequent
- 398 measles vaccine doses: a systematic review and meta-analysis. Lancet Infect Dis.
- 399 2019;19(11):1246–54.
- 400




Age groups

# Figure 2A




Age groups

# Figure 2B



Months

# Figure 1A



Months

# Figure 1B